XY 018

Key Product Details

Product Description

XY 018 is a RORγ antagonist (EC₅₀ = 190 nM). Suppresses androgen receptor expression in prostate cancer cell lines. Also inhibits growth of tumors in androgen receptor-positive xenograft models.

Product Specifications for XY 018

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for XY 018

The following data is based on the product molecular weight 516.36.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.94 mL	9.68 mL	19.37 mL
5 mM	0.39 mL	1.94 mL	3.87 mL
10 mM	0.19 mL	0.97 mL	1.94 mL
50 mM	0.04 mL	0.19 mL	0.39 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ndagi Re-emergence of an orphan therapeutic target for the treatment of resistant prostate cancer - a through conformational and binding analysis for RORγ protein. J.Biomol.Struct.Dyn. 2018 PMID: 28027708
• Wang ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat.Med. 2016 PMID: 27019329

Product Documents for XY 018